Drug Interaction Report

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations and the risk of adverse effects of rucaparib, which has been shown in vitro to be a substrate of the isoenzyme. However, the effects on the pharmacokinetics of rucaparib have not been evaluated in vivo.

MANAGEMENT: Caution is advised if rucaparib is used concomitantly with potent CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy with rucaparib.

ADJUST DOSING INTERVAL: Food significantly enhances the oral bioavailability of boceprevir. When given at 800 mg three times daily with food, boceprevir exposure increased by up to 65% relative to administration in the fasting state. The bioavailability of boceprevir was similar regardless of meal type (e.g., high-fat versus low-fat) or whether taken 5 minutes prior to eating, during a meal, or immediately following completion of the meal. Therefore, boceprevir may be taken without regard to either meal type or timing of the meal.

MANAGEMENT: To ensure maximal oral absorption, boceprevir should be administered with a meal or light snack.